廣濟藥業(000952.SZ)2019年度淨利潤降49.37%至8694.32萬元 擬10送2派0.7元
格隆匯4月23日丨廣濟藥業(000952.SZ)發佈2019年年度報告,實現營業總收入7.31億元,同比下降13.33%;歸屬於上市公司股東的淨利潤8694.32萬元,同比下降49.37%;歸屬於上市公司股東的扣除非經常性損益的淨利潤5102.21萬元,同比下降69.17%;基本每股收益0.35元,擬每10股派發現金紅利0.7元(含税),送紅股2股(含税)。
公司主要產品分為原料系列產品、製劑系列產品,其中:原料系列產品為醫藥級、食品級、98%飼料級、80%飼料級核黃素及核黃素磷酸鈉;製劑系列產品為口服固體制劑和大輸液。
公司主導產品維生素B2又稱核黃素。維生素B2廣泛應用於醫藥原料藥、飼料添加劑、食品添加劑等領域,具有廣泛的生理功能,可以在微生物和高等植物體內合成,而動物和人類則不能,必須從食物中攝取,因而被世界衞生組織列為評價人體生長髮育和營養狀況的六大指標之一,其在臨牀醫療、飼料加工、食品工業及化粧品製造等領域均有重要價值。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.